SoftGenetics
Private Company
Funding information not available
Overview
Founded in 2000, SoftGenetics has established itself as a specialized provider of analytical software for genetics and genomics. The company's core business is a portfolio of software tools, including NextGENe® for sequencing analysis and GeneMarker® for fragment analysis, which enable researchers and forensic labs to analyze complex genetic data with speed and accuracy. It operates a platform-plus-products model, offering both a unifying scientific R&D platform (Luma) and standalone point solutions, generating revenue through software licensing and subscriptions. As a private company, it focuses on expanding its AI-powered automation capabilities to capture a larger share of the growing bioinformatics and computational biology market.
Technology Platform
Luma scientific intelligence platform for AI-powered data management and workflow automation, plus a suite of specialized software for genetic sequencing analysis, fragment analysis, forensic DNA analysis, bioinformatics, proteomics, and electronic lab notebook functions.
Opportunities
Risk Factors
Competitive Landscape
SoftGenetics competes in a fragmented but competitive market. It faces large, diversified competitors like Illumina (DRAGEN), Thermo Fisher, and QIAGEN in NGS analysis, and other specialized software vendors like DNASTAR, Partek, and Golden Helix. In forensics, it competes with Promega's GeneMapper and other accredited software. Its platform strategy also brings it into competition with ELN and informatics providers like Benchling and BioVia.